Aim To determine the appropriate timing of cardiac troponin T (cTnT) measurement for the early triage of pulmonary embolism (PE) patients.
MethodsIn this single-center prospective study, PE was confirmed in all patients using computed tomography. 104 consecutive patients were divided into three groups (high-risk, intermediate, and low-risk) based on their hemodynamic status and echocardiographic signs of right ventricular dysfunction. cTnT levels were measured on admission and then after 6, 24, 48, and 72 hours with threshold values greater than 0.1 ng/mL.
ResultsIntermediate-risk PE patients had higher cTnT levels than low-risk patients already in the first measurement (P = 0.037). Elevated cTnT levels significantly correlated with disease severity after 6 hours (intermediate vs low risk patients, P = 0.016, all three groups, P = 0.009).
ConclusionIn hemodynamically stable patients, increased cTnT level on admission differentiated intermediate from low-risk patients and could be used as an important element for the appropriate triage of patients. Timing of troponin T measurements in triage of pulmonary embolism patients CLINICAL SCIENCE Croat Med J. 2013;54:561-8 doi: 10.3325/cmj.2013.54.561 CLINICAL SCIENCE 562
Nikola Bulj1Croat Med J. 2013;54:561-8 www.cmj.hrPulmonary embolism (PE) still remains one of the most frequent causes of death among patients in emergency settings. Early identification of high-risk patients and optimal treatment administration is often difficult due to the clinical variability of the disease. Several risk-stratification tools have been recently proposed based on echocardiography, biomarkers (troponins and natriuretic peptides), and computed tomography (1). Right ventricular dysfunction (RVD) is a central hemodynamic event in PE patients, and represents an independent prognostic factor of adverse events. Multiple clinical studies have convincingly shown that RVD in hypotensive and normotensive PE patients directly affects early mortality (2). A meta-analysis by ten Wolde et al clearly indicates that RVD is associated with a two times higher risk of PE related mortality (3). According to the current European Society of Cardiology (ESC) guidelines, therapy should be tailored to the estimated risk of death due to acute pulmonary embolism (4). The guidelines divide PE patients into three groups: high-risk (PE related mortality risk >15%), intermediate (PE related mortality risk 3%-15%), and low-risk patients (PE related mortality risk <1%) based on the presence of right ventricular dysfunction (measured by echocardiography, computed tomography, and natriuretic peptides) or injury (troponins). Higher risk patients should be treated with thrombolytic therapy in an intensive care unit (ICU), while non-high-risk patients should be additionally stratified and treated either in an ICU (intermediate-risk) or clinical ward (low-risk patients).Laboratory evaluations of acute right ventricular injury in PE patients have been extensively performed over the past few years, with a special emph...